Activity in Tourette Syndrome

Status Completed

Clinical Trial Summary

Tics are brief repetitive movements or vocalizations. Gilles de la Tourette's syndrome (TS) is a disorder characterized by recurrent motor and vocal tics. Tourette syndrome and tic disorders affect up to 8% of children. Peak severity of tic disorders occurs between the ages of 8 to 12 years, therefore during childhood and adolescence the most significant impacts are felt. The quality of life of young people with tics is lower than their peers' and tic severity predicts lower quality of life. Studies have also shown negative social perception toward children with tics.

Approximately 50% of patients with Tourette syndrome will have other diagnoses including attention deficit hyperactivity disorder (ADHD), obsessive compulsive disorder, anxiety and depression. Studies have shown improvements in ADHD with physical activity. ADHD and tic disorders are thought to involve the same areas of the brain; thus it is possible that tics might also improve with physical activity. However, no studies to date have examined this. The investigators predict that by implementing a motivational physical activity program, in conjunction with physical activity counseling, the investigators will be able to increase levels of physical activity in children with tics and Tourette syndrome, with a positive impact on tic severity.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02153463
Study type	Interventional
Source	Children's Hospital of Eastern Ontario
Contact
Status	Completed
Phase	N/A
Start date	May 2014
Completion date	December 2014

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04851678` - Longitudinal Impact of Stressors in Adults With Tourette Syndrome
Completed	`NCT02605902` - Trial to Demonstrate the Efficacy and Safety of Internet-delivered Behavioral Treatment for Adults With Tic Disorders	N/A
Completed	`NCT04007913` - Incorporating teleCBIT Into a Hospital-Based Tic Program	N/A
Completed	`NCT02900144` - Modified Comprehensive Behavioral Intervention for Tics (M_CBIT)	N/A
Completed	`NCT02216474` - Brain Stimulation in Movement Disorders	N/A
Completed	`NCT02256475` - Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome	Phase 1
Completed	`NCT01329198` - Brain Stimulation for the Treatment of Tourette Syndrome	N/A
Terminated	`NCT00952601` - Pilot Study of the Modified Atkins Diet for Tourette Syndrome	Phase 1
Enrolling by invitation	`NCT00355927` - Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders.	N/A
Completed	`NCT00206323` - A Randomized, Placebo-controlled, Tourette Syndrome Study.	Phase 3
Completed	`NCT00004376` - Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder	Phase 3
Completed	`NCT04498364` - Extinction Learning in Adults With Tourette Syndrome	N/A
Completed	`NCT00755339` - Role of the Sensory Experience in Generating Motor Tics in Tourette Syndrome
Completed	`NCT03325010` - Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome	Phase 2
Not yet recruiting	`NCT06081348` - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders	Phase 2
Completed	`NCT01719523` - Open-Trial of EPI-743 for Adults With Tourette Syndrome	Phase 1
Completed	`NCT01702077` - Neurofeedback for Tourette Syndrome	N/A
Completed	`NCT00231985` - Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder	Phase 2
Completed	`NCT00206336` - An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.	Phase 3
Terminated	`NCT03732534` - Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome	Phase 2